Loefflers syndrome differential diagnosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 35: | Line 35: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ELISA | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |ELISA | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CXR | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CXR | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CT Scan | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 3 | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging 3 | ||
|- | |- | ||
Line 81: | Line 81: | ||
eosinophilia | eosinophilia | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |cough, breathlessness, wheezing, fatigue, and fever. | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 88: | Line 88: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |40 to 70 percent | | style="background: #F5F5F5; padding: 5px;" |40 to 70 percent | ||
(>3000/microL) | |||
plus elevated IgE levels ( >1000 units/mL) | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Diffuse opacities | |||
* Around 20% of patients have a normal CXR | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Reticular and small nodular opacities | |||
* Bronchiectasis | |||
* Air trapping | |||
* Calcification | |||
* Mediastinal adenopathy | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 140: | Line 150: | ||
ELISA is generally positive while stool examination is often negative. | ELISA is generally positive while stool examination is often negative. | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
'''Strongyloides:''' diffuse ground glass opacities | '''Strongyloides:''' diffuse ground glass opacities | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 176: | Line 185: | ||
| rowspan="2" |Nonhelminthic infections | | rowspan="2" |Nonhelminthic infections | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis | ||
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 184: | Line 194: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Antibody testing may be negative early in the course of disease | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 193: | Line 203: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 228: | Line 237: | ||
| colspan="2" |Drug- and toxin-induced eosinophilic lung diseases | | colspan="2" |Drug- and toxin-induced eosinophilic lung diseases | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* asymptomatic pulmonary infiltration with eosinophils, chronic cough with or without dyspnea and fever, acute eosinophilic pneumonia, and | |||
* DRESS should be suspected when the patient has a skin eruption, fever, facial edema, enlarged lymph nodes, and a history of initiation of a culprit medication two to six weeks prior to disease onset | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 242: | Line 253: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* '''Medications such as:''' | |||
* Nonsteroidal antiinflammatory drugs | * Nonsteroidal antiinflammatory drugs | ||
* Phenytoin | * Phenytoin | ||
* L-tryptophan | * L-tryptophan | ||
* Antibiotics (nitrofurantoin, minocycline, sulfonamides, ampicillin, daptomycin) | * Antibiotics (nitrofurantoin, minocycline, sulfonamides, ampicillin, daptomycin) | ||
* '''Toxins such as:''' | |||
* Aluminum silicate and particulate metals •Sulfite •Scorpion stings •Inhalation of o heroin, crack cocaine, or marijuana •Inhalation of organic chemicals, dust or smoke, during rubber manufacture, fireworks, firefighting, tobacco smoking •Abuse of 1,1,1-trichloroethane (Scotchgard) | |||
|- | |- | ||
| | | |
Revision as of 16:12, 21 May 2019
![](/images/1/16/Home_logo1.png)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Loeffler syndrome must be differentiated from other diseases that cause pulmonary eosinophilia, such as Churg-Strauss, drug and toxin-induced eosinophilic lung diseases, other helminthic and fungal infection related eosinophilic lung diseases, and nonhelminthic infections such as Coccidioidomycosis, and Mycobacterium tuberculosis.
Differentiating Loeffler syndrome from other pulmonary eosinophilia syndromes on the basis of etiology.
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||||||
Physical exam 2 | Physical exam 3 | Increased Eosinophil count
(High) |
Increased Eosinophil count
(Mild to moderate) |
ELISA | CXR | CT Scan | Imaging 3 | |||||||||
Helminthic
and fungal infection-related eosinophilic lung diseases |
Transpulmonary
passage of larvae (Loffler's syndrome) |
Cough
Sputum production Wheezing Fever |
|
| ||||||||||||
Tropical
pulmonary eosinophilia |
cough, breathlessness, wheezing, fatigue, and fever. | 40 to 70 percent
(>3000/microL) plus elevated IgE levels ( >1000 units/mL) |
|
|
| |||||||||||
Allergic bronchopulmonary aspergillosis | * | |||||||||||||||
Heavy
hematogenous seeding with helminths |
depends on the organism for example:
periorbital edema, myositis, and eosinophilia (Trichinellosis) |
* | * | Trichinellosis: will be positive 2-8 weeks after infection
Strongyloides: ELISA is generally positive while stool examination is often negative. |
Strongyloides: diffuse ground glass opacities |
| ||||||||||
Pulmonary parenchymal invasion | Eosinophilia is prominent in the early stages of disease but minimal with established disease | Useful in later infection with Paragonimus |
|
Finding eggs in the sputum or bronchoalveolar lavage fluid |
| |||||||||||
Nonhelminthic infections | Coccidioidomycosis | Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure |
|
|||||||||||||
Mycobacterium tuberculosis | ||||||||||||||||
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) | * | |||||||||||||||
Drug- and toxin-induced eosinophilic lung diseases |
|
* |
| |||||||||||||
Acute eosinophilic pneumonia | ||||||||||||||||
Chronic eosinophilic pneumonia | ≥40 percent | |||||||||||||||
Idiopathic acute eosinophilic pneumonia | ≥25 percent | |||||||||||||||
Diseases | Symptom 1 | Symptom 2 | Symptom 3 | Physical exam 1 | Physical exam 2 | Physical exam 3 | Increased Eosinophil count
(High) |
Increased Eosinophil count
(Mild to moderate) |
ELISA | Imaging 1 | Imaging 2 | Imaging 3 | Histopathology | Gold standard | Additional findings | |
Sarcoidosis | * | |||||||||||||||
Pulmonary Langerhans cell histiocytosis (Histiocytosis X) | * | |||||||||||||||
Idiopathic pulmonary fibrosis | <10 percent | |||||||||||||||
Differential Diagnosis 7 |